Get started
Work

976P Phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): Registrational data from DESTINY-Lung01

Year: 2022
Type: article
DOI: 10.1016/j.annonc.2022.07.1104
Authors: B.T. Li, E.F. Smit, Y. Goto, K. Nakagawa, K. Goto, J. Mazieres, D. Uprety, L. Bazhenova, A. Saltos, E. Felip, J. Pacheco, M. Pérol, L. Paz-Ares, K. Saxena, R. Shiga, Y. Cheng, Q. Yan, D. Planchard, P.A. Jänne
Institutions: Memorial Sloan Kettering Cancer Center, The Netherlands Cancer Institute, National Cancer Center Hospital, Kindai University Hospital, National Cancer Center Hospital East, Centre Hospitalier Universitaire de Toulouse, Hôpital Larrey, The Barbara Ann Karmanos Cancer Institute, University of California San Diego, Moores Cancer Center, Moffitt Cancer Center, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, University of Colorado Anschutz, Centre Léon Bérard, Hospital Universitario 12 De Octubre, Daiichi Sankyo (United States), Institut Gustave Roussy, Fondation Gustave Roussy, Dana-Farber Cancer Institute
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W4295819468
FWCI: 0.851
Cites:
Cited by: 7
Related to: 10